Author

Renata Zaucha

Observed names: R Zaucha, R. Zaucha, R.E. Zaucha, Renata E Zaucha, Renata E. Zaucha, Zaucha, Renata, Zaucha, Renata; Katedra i Klinika Onkologii i Radioterapii, Gdański Uniwersytet Medyczny

Institutions: University Clinical Centre, Gdańsk Medical University

Observed institutions: Mayo Clinic, The University of Texas MD Anderson Cancer Center, University of Washington, University Hospital of Bern, Paul Scherrer Institute, Fred Hutch Cancer Center, Institut Català d'Oncologia, Greater Poland Cancer Center, University Clinical Centre, Gdańsk Medical University, Medical University of Vienna

ORCID: 0000-0001-8503-1559

Observed ORCID: 0000-0001-8503-1559

OpenAlex ID: A5079728501

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

2022 · Do-Youn Oh, Aiwu Ruth He, et al. · NEJM Evidence · 1,370

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

2021 · Thomas Yau, Joong-Won Park, et al. · The Lancet Oncology · 1,195

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

2020 · Thomas Powles, Michiel S van der Heijden, et al. · The Lancet Oncology · 518

PDF

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

2023 · Kim N. Chi, Dana Rathkopf, et al. · Journal of Clinical Oncology · 386

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

2024 · Do-Youn Oh, Aiwu Ruth He, et al. · The Lancet. Gastroenterology & hepatology · 364

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

2022 · Do-Youn Oh, Aiwu Ruth He, et al. · Journal of Clinical Oncology · 236

CD34 cell dose in granulocyte colony-stimulating factor–mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen–identical sibling transplantation

2001 · J. Maciej Zaucha, Theodore Gooley, et al. · Blood · 229

Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network

2014 · D. C. Weber, Y. Wang, et al. · Neuro-Oncology · 137

PDF

The Results of Surgery, With or Without Radiotherapy, for Primary Spinal Myxopapillary Ependymoma: A Retrospective Study From the Rare Cancer Network

2009 · Alessia Pica, Robert Miller, et al. · International Journal of Radiation Oncology*Biology*Physics · 120

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study

2025 · Do-Youn Oh, Aiwu Ruth He, et al. · Journal of Hepatology · 119

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

2025 · Maria De Santis, Joan Palou Redorta, et al. · The Lancet · 104

Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study

2013 · J.A. Ajani, M. Buyse, et al. · European Journal of Cancer · 82

The role of PET/CT in the modern treatment of Hodgkin lymphoma

2019 · Jan Maciej Zaucha, Stephane Chauvie, et al. · Cancer Treatment Reviews · 76

The Essential Role of Radiotherapy in the Treatment of Merkel Cell Carcinoma: A Study From the Rare Cancer Network

2011 · Pirus Ghadjar, Johannes H. Kaanders, et al. · International Journal of Radiation Oncology*Biology*Physics · 75

2017 · Monika Ziętarska, Joanna Krawczyk-Lipiec, et al. · Nutrients · 72

PDF

BRCA1 and BRCA2 Mutations in Women from Shanghai China

2004 · Nicola M. Suter, Roberta M. Ray, et al. · Cancer Epidemiology Biomarkers & Prevention · 72

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study

2025 · K. Fizazi, N.W. Clarke, et al. · Annals of Oncology · 71

PDF

Plausible Role of Estrogens in Pathogenesis, Progression and Therapy of Lung Cancer

2021 · Claudia Musial, Renata Zaucha, et al. · International Journal of Environmental Research and Public Health · 48

PDF

Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma

2014 · Ewa Bednaruk-Młyński, Joanna Pieńkowska, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 38

Nutritional status assessment in colorectal cancer patients qualified to systemic treatment

2017 · Monika Ziętarska, Joanna Krawczyk-Lipiec, et al. · Współczesna Onkologia · 34

PDF

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

2013 · R Plummer, P Lorigan, et al. · British Journal of Cancer · 30

PDF

78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

2022 · D-Y. Oh, A.R. He, et al. · Annals of Oncology · 28

Changes of systemic immune response after stereotactic ablative radiotherapy (SABR) - first results of a prospective study in early lung cancer patients

2017 · Jacek Rutkowski, Tomasz Ślebioda, et al. · Polskie Archiwum Medycyny Wewnętrznej · 27

Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma.

2018 · Padmanee Sharma, Luc Dirix, et al. · Journal of Clinical Oncology · 26

Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.

2023 · Mohamed Bouattour, Juan W. Valle, et al. · Journal of Clinical Oncology · 24

Works count: 115

Citation count: 5,853

H-index: 24

I10-index: 40